Barclays raised the firm’s price target on Privia Health (PRVA) to $23 from $21 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for the managed care space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health enters Arizona in partnership with Integrated Medical Services
- Buy Rating for Privia Health Group: Stability and Growth Amid Medicare Model Changes
- Privia Health Group: Strong Execution and Growth Potential with Revised Price Target
- Privia Health price target raised to $29 from $26 at Citizens JMP
- Privia Health Group: Strong Financial Performance and Strategic Positioning Justify Buy Rating and Increased Price Target